000			01935cam a2200217 4500500
005			20250121143330.0
041			_afre
042			_adc
100	1	0	_aBentounes, Nûn K. _eauthor
700	1	0	_a Melicine, Sophie _eauthor
700	1	0	_a Céline Martin, Anne _eauthor
700	1	0	_a Smadja, David M. _eauthor
700	1	0	_a Gendron, Nicolas _eauthor
700	1	0	_a Gendron, Nicolas _eauthor
245	0	0	_aNew anticoagulants in 2024: The development of factor XI and XIa inhibitors
260			_c2024.
500			_a94
520			_aThrombosis remains one of the leading causes of death worldwide. The history of anticoagulation has evolved considerably, from non-specific drugs (i.e., heparins and vitamin K antagonists [VKAs]) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux, and direct oral anticoagulants [DOACs]). Over the past decade, DOACs have been widely used in clinical practice because of their ease of use, favorable pharmacological profile, and lack of need for laboratory monitoring. However, despite having a better safety profile than VKAs, their risk of causing hemorrhagic events remains and is a feared side effect. New anticoagulants targeting the contact phase of coagulation are currently being developed and could potentially prevent the risk of thrombosis without impairing hemostasis, thereby reducing the bleeding risk. Observational and preclinical data on factor XI (FXI) deficiency make FXI a promising therapeutic target. The aim of this review is to summarize the results of the various clinical trials available that focus on FXI/FXIa inhibition, and to highlight the challenges that this new therapeutic class of anticoagulants will face.
786	0		_nSang Thrombose Vaisseaux | Volume 36 | 5 | 2024-12-04 | p. 197-209 | 0999-7385
856	4	1	_uhttps://shs.cairn.info/journal-sang-thrombose-vaisseaux-2024-5-page-197?lang=en&redirect-ssocas=7080
999			_c586899 _d586899